Home » Stocks » CMRX

Chimerix, Inc. (CMRX)

Stock Price: $8.44 USD -0.01 (-0.12%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $8.45 +0.01 (0.12%) Jun 11, 5:01 PM
Market Cap 727.62M
Revenue (ttm) 5.57M
Net Income (ttm) -130.52M
Shares Out 80.20M
EPS (ttm) -1.95
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $8.44
Previous Close $8.45
Change ($) -0.01
Change (%) -0.12%
Day's Open 8.50
Day's Range 8.42 - 8.66
Day's Volume 493,519
52-Week Range 2.22 - 11.57

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

– First smallpox antiviral approved for all age groups, including infants, and patients who have difficulty swallowing – – First smallpox antiviral approved for all age groups, including infants, and pa...

1 week ago - GlobeNewsWire

DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today ...

3 weeks ago - GlobeNewsWire

– BCV PDUFA Date Set for July 7 and ONC201 Blinded Independent Central Review Expected in Second Half of 2021 –

1 month ago - GlobeNewsWire

Chimerix (CMRX) has been struggling lately, but the selling pressure may be coming to an end soon

1 month ago - Zacks Investment Research

DURHAM, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

1 month ago - GlobeNewsWire

DURHAM, N.C., April 26, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

1 month ago - GlobeNewsWire

DURHAM, N.C., April 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

2 months ago - GlobeNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: AFMD, EPZM, SEEL, WVE
2 months ago - 24/7 Wall Street

DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, toda...

3 months ago - GlobeNewsWire

WESTON, Fla., Feb. 26, 2021 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing proprietary pharmaceuticals for the treatment of inflammatory lung disease...

3 months ago - PRNewsWire

Chimerix Inc (NASDAQ: CMRX) reports topline results from the first cohort (n=12) of its Phase 2/3 study evaluating DSTAT in hospitalized patients with Acute Lung Injury (ALI) and COVID-19 infection. The...

3 months ago - Benzinga

Billionaire investor Steven Cohen (Trades, Portfolio), who leads Point72 Asset Management, disclosed a 5.37% stake in Chimerix Inc. (NASDAQ:CMRX) earlier this week.

3 months ago - GuruFocus

DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...

4 months ago - GlobeNewsWire

DURHAM, N.C., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...

4 months ago - GlobeNewsWire

DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases...

4 months ago - GlobeNewsWire

A new acquisition could be quite the shot in the arm for the company.

5 months ago - The Motley Fool

ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma

5 months ago - GlobeNewsWire

Chimerix's (CMRX) NDA for brincidofovir as a medical countermeasure for smallpox has been accepted by the FDA.

6 months ago - Zacks Investment Research

FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021 FDA Grants Priority Review and Sets PDUFA Date for April 7, 2021

6 months ago - GlobeNewsWire

Chimerix, Inc. (CMRX) CEO Michael Sherman on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

DURHAM, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...

7 months ago - GlobeNewsWire

DURHAM, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today...

7 months ago - GlobeNewsWire

DURHAM, N.C., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, to...

9 months ago - GlobeNewsWire

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Chimerix (CMRX) delivered earnings and revenue surprises of 11.11% and 19.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

Shares of Chimerix (NASDAQ:CMRX) were flat in pre-market trading after the company reported Q2 results.

10 months ago - Benzinga

DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, tod...

10 months ago - GlobeNewsWire

Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise Former Eli Lilly Veteran Brings Deep Oncology Clinical and Regulatory Expertise

11 months ago - GlobeNewsWire

Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.

Other stocks mentioned: ATHX, CTSO, CYDY, MESO
1 year ago - Seeking Alpha

Chimerix (CMRX) delivered earnings and revenue surprises of -13.33% and -17.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Shares of Chimerix (NASDAQ:CMRX) were unchanged at $2.52 after the company reported Q1 results.

1 year ago - Benzinga

FDA Clearance to Proceed with Phase 2/3 Randomized, Double-Blind, Placebo Controlled Study

1 year ago - GlobeNewsWire

DURHAM, N.C., April 28, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, to...

1 year ago - GlobeNewsWire

Chimerix (CMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Chimerix, Inc. (CMRX) CEO Mike Sherman on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Brincidofovir demonstrated a statistically significant survival advantage in two well-characterized animal models of lethal orthopoxvirus infection Brincidofovir demonstrated a statistically significant...

1 year ago - GlobeNewsWire

Is (CMRX) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

DURHAM, N.C., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseas...

1 year ago - GlobeNewsWire

Chimerix's (CMRX) CEO Michael Sherman on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Includes All Human Indications Excluding Prevention and Treatment of Smallpox

1 year ago - GlobeNewsWire

Chimerix (CMRX) delivered earnings and revenue surprises of -105.88% and -37.48%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Chimerix (CMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor Chimerix.

2 years ago - Zacks Investment Research

Chimerix's (CMRX) CEO Mark Iwicki on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

Chimerix (CMRX) delivered earnings and revenue surprises of 0.00% and 17.80%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

Chimerix (CMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

News of changes to its executive team boosted Chimerix Inc. shares on Tuesday. Specifically, the firm announced the appointment of Michael A. Sherman as chief executive of Chimerix, effective immediately.

2 years ago - 24/7 Wall Street

About CMRX

Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox; dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy; and ONC201 ... [Read more...]

Industry
Biotechnology
IPO Date
Apr 11, 2013
CEO
Michael Sherman
Employees
54
Stock Exchange
NASDAQ
Ticker Symbol
CMRX
Full Company Profile

Financial Performance

In 2020, Chimerix's revenue was $5.37 million, a decrease of -57.09% compared to the previous year's $12.52 million. Losses were -$43.52 million, -61.34% less than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Chimerix stock is "Buy." The 12-month stock price forecast is 17.83, which is an increase of 111.26% from the latest price.

Price Target
$17.83
(111.26% upside)
Analyst Consensus: Buy